Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis. Issue 8 (13th July 2021)

• Record Type: Journal Article
• Authors: Martelletti, Carolina; Ricotti, Andrea; Gesualdo, Marcantonio; Carucci, Patrizia; Gaia, Silvia; Rolle, Emanuela; Burlone, Michela Emma; Okolicsanyi, Stefano; Mattalia, Alberto; Pirisi, Mario; Berchialla, Paola; Tabone, Marco
• Is Part Of: Journal of digestive diseases. Volume 22:Issue 8(2021)
• Page Start: 496
• Page End: 502
• Publication Date: 2021-07-13
• Subjects: hepatocellular carcinoma -- portal vein tumor thrombosis -- sorafenib -- transarterial radioembolization -- yttrium‐90 microsphere; Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.13030
• Languages: English
• ISSNs: 1751-2972

Abstract

Abstract : Objective: In this study we aimed to compare patient outcomes between the use of transarterial radioembolization (TARE) and sorafenib in patients with hepatocellular carcinoma (HCC) and intrahepatic portal vein tumor thrombosis (PVTT). Methods: A total of 65 patients with HCC and intrahepatic PVTT treated in five Italian hospitals between 2012 and 2018 were included in the analysis. Those with any previous treatment, extension of PVTT to the main portal tract and extrahepatic involvement were excluded. Propensity score matching analysis and Bayesian model averaging analysis were performed. Results: Of the 41 patients treated with TARE and 24 with sorafenib, 11 patients were downstaged to curative‐intent surgery (liver transplant in three and hepatectomy in eight), including 10 treated with TARE and one with sorafenib. TARE was more effective than sorafenib in downstaging patients to surgery, achieving a mean survival of 54 months. In the 54 patients without downstaging after treatment, of whom 31 were treated with TARE and 23 with sorafenib, median survival was 20.3 and 9.1 months, respectively ( P = 0.001), with different 1‐, 2‐ and 3‐year OS rates (64.5%, 42.6% and 37.3% vs 39.1%, 13.0% and 0%). Both propensity score and Bayesian model averaging confirmed an improvement in overall survival in the TARE group compared with sorafenib treatment. Conclusions: TARE was more effective than sorafenib in downstaging patients with HCC to surgery, providing a significant improvement in survival. Even in patients who were not downstaged to surgery, survival appeared to be superior with TARE over sorafenib. Abstract : Transarterial radioembolization is an alternative option to sorafenib in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) limited to the intrahepatic branches (Vp1‐Vp3).